November 15, 2019 / 12:14 PM / 21 days ago

BRIEF-Jazz Pharma's sleep disorder drug gets European panel backing

Nov 15 (Reuters) - EMA:

* EMA - CHMP RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR ISTURISA (OSILODROSTAT) FOR THE TREATMENT OF CUSHING’S SYNDROME

* EMA - TAVLESSE (FOSTAMATINIB) RECEIVED A POSITIVE OPINION FROM CHMP FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA

* EMA - CHMP ADOPTED A POSITIVE OPINION FOR SUNOSI FOR TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY & OBSTRUCTIVE SLEEP APNOEA

* EMA - CHMP RECOMMENDS RESTRICTING USE OF MULTIPLE SCLEROSIS MEDICINE LEMTRADA (ALEMTUZUMAB) DUE TO REPORTS OF RARE BUT SERIOUS SIDE EFFECTS

* EMA - CHMP RECOMMENDS CONDITIONAL MARKETING AUTHORISATION FOR POLIVY (POLATUZUMAB VEDOTIN) TO TREAT RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

* EMA - MAYZENT GOT POSITIVE OPINION FROM CHMP FOR TREATMENT OF ADULT PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS WITH ACTIVE DISEASE Source (bit.ly/33Q89N3) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below